Actos Buyers Fight Takeda Appeal Bid In Drug Delay Case
Law360 (December 16, 2019, 6:03 PM EST) -- End payors and direct buyers of the diabetes drug Actos have urged a New York federal judge to nix Takeda’s bid to immediately appeal her decision preserving some class action claims against the drugmaker, which they have accused of using patent suits to hold off generic competitors.
The Japanese pharmaceutical firm has pushed for Second Circuit review of U.S. District Judge Ronnie Abrams’ November ruling that kept intact the end-payor claims while also preserving some of the litigation by direct buyers. The suits from a range of Actos purchasers accuse Takeda of filing multiple patent claims to force challenges from generic makers and...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!